Status:
COMPLETED
Transcranial Direct Current Stimulation (tDCS) Therapy in Major Depression
Lead Sponsor:
University of California, Los Angeles
Collaborating Sponsors:
National Institutes of Health (NIH)
National Institute of Mental Health (NIMH)
Conditions:
Major Depressive Disorder
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Noninvasive transcranial direct current stimulation (tDCS) is a low-intensity neuromodulation technique of minimal risk that has been used as an experimental procedure for reducing depressive symptoms...
Detailed Description
Transcranial direct current stimulation (tDCS), a noninvasive neuromodulation technique, applied to the left dorsolateral prefrontal cortex (DLPFC) can reduce depressive symptoms and improve cognitive...
Eligibility Criteria
Inclusion
- Capacity to provide informed consent;
- Meet DSM-5 criteria for a moderate-to-severe MDE, with Hamilton Rating Scale for Depression (HAMD) score of ≥14 and \<24;
- Treatment naïve or on a stable standard antidepressant regimen (including selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MOAIs) or tricyclic's (TCAs)) with no change in treatment 6-weeks prior to and during the tDCS intervention;
- Live within traveling distance to the University of California, Los Angeles (UCLA);
- Must refrain from making drastic hair-style changes throughout duration of study
Exclusion
- Non-English speaking;
- Schizophrenia Axis I disorder;
- Primary anxiety disorder;
- Bipolar I disorder and psychotic disorders;
- Any neurological condition or major illness, including seizure disorder;
- Diagnosis of dementia of any type;
- Co-morbid substance abuse in the last three months;
- Contraindications to MR scanning (including pregnancy);
- Contraindications to tDCS (e.g., skin disease or treatment causing irritation);
- Treatment-resistant depression, with a history of a major depressive episode lasting \> 2 years or failure to 2 or more antidepressant trials in the current episode;
- Any neuromodulation therapy (e.g., ECT, rTMS, DBS, VNS, or tDCS) within the last 3 months;
- Active suicidality;
- Current or past (within the last 1-month) use of anticonvulsants, lithium, psychostimulants, or dexamphetamine;
- Current use of decongestants or other medication previously shown to interfere with cortical excitability;
- Currently receiving any form of Cognitive Behavioral Therapy, Dialectical Behavioral Therapy, or Acceptance and Commitment Therapy
Key Trial Info
Start Date :
December 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 7 2024
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT04507243
Start Date
December 1 2020
End Date
March 7 2024
Last Update
April 30 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, Los Angeles (UCLA)
Los Angeles, California, United States, 90095